CalciMedica, Inc. — Form 8-K Summary
Reporting date: September 30, 2026. This current report concerns a financing authorization, not quarterly or annual financial results.
Business and offering
CalciMedica filed a prospectus supplement allowing it to offer and sell up to $25 million of common stock from time to time through an at-the-market offering agreement with H.C. Wainwright & Co., originally dated August 11, 2023. The offering is under the company’s Form S-3 shelf registration statement, filed March 3, 2026 and declared effective March 11, 2026.
Financial metrics and changes
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other operating results, and does not state that any shares have been sold or disclose proceeds received. The potential offering represents an opportunity to raise up to $25 million; actual proceeds and share issuance are not reported.
Outlook, risks, and unusual items
No financial guidance or operating outlook is provided. If shares are sold, the offering could dilute existing stockholders; the filing does not specify the timing, volume, or price of any sales. The company included a legal opinion regarding the legality of the shares covered by the prospectus supplement.
Key facts for investors to verify
- Whether and when CalciMedica sells shares under the ATM program, and the resulting gross and net proceeds.
- The number and price of shares issued and the effect on existing stockholders’ ownership.
- Updated cash, liquidity, and capital needs in the company’s subsequent financial filings.